ABCEurope Virtual Matchmaking Event on Oncology – Company profiles 13 and 14 February 2012
Contents ABLE Biosciences ...... 2 Aldevron Freiburg GmbH ...... 4 Allosterix Ltd ...... 5 Almetis ...... 7 AlphaSzenszor Inc...... 8 Argon Pharma ...... 9 Astrid Research Kft ...... 11 Biognos AB ...... 12 BioMarCare Technologies Ltd...... 13 Biomotif AB ...... 15 ChemCon GmbH ...... 16 EPHORAN MULTI IMAGING SOLUTIONS ...... 17 GenIbet Biopharmaceuticals ...... 19 iBET - Instituto de Biologia Experimental e Tecnológica...... 20 IDD Therapeutics Ltd...... 22 im3D S.p.A...... 24 Intelligent Pharma...... 25 I-SEE ...... 26 LEITAT - Biomed Division ...... 28 lipocure Ltd ...... 30 Pathology Diagnostics ...... 31 PROCELLTECH SRL ...... 33 Promec Elettronica SrL ...... 35 ProQinase GmbH ...... 36 SATT Conectus Alsace ...... 38 SOM Biotech ...... 39 Theradex (Europe) Ltd ...... 40 TRANSGENE SA ...... 41 UROLEAD SAS ...... 42
ABLE Biosciences Turin, Italy -www.ablebiosciences.com
ABLE Biosciences is a CRO providing bioanalytical, analytical, biomarkers and proteomic services to customers as a key part of the drug and diagnostic development process. ABLE Biosciences (Analytical and Biological Laboratories and Expertise in Biosciences) is the CRO arm of Bioindustry Park Silvano Fumero S.p.A. We are the partner of choice for pharmaceutical, biotechnology, and research customers requiring scientific excellence in their contract bioanalytical, analytical, biomarkers and proteomic services. ABLE Biosciences' range of services is employed by customers as a key part of the drug and diagnostic development process. ABLE Biosciences uses advanced techniques and state-of-the-art equipment to provide fast turnaround times, quality and precision. Our deep scientific expertise enables us to provide a portfolio of services characterized by scientific excellence, quality, flexibility, and regulatory compliance. ABLE Biosciences' scientific and management team has a track record of progressing technology solutions and delivering first-class services to the market. The company has worked with international pharmaceutical companies resulting in several Master Service Agreements being placed. ABLE Biosciences continues to invest in cutting-edge technologies and form strategic alliances to offer the best quality and most comprehensive services to its pharmaceutical and biotech customers. Our vision is to be recognized by our clients as a trusted partner and a leading CRO in providing research and development services that produce new drugs and treatments in a broad range of therapeutic areas, which improve health, quality of life, and may ultimately save lives. Our philosophy is working with our clients with passion, consistency, commitment, and a sense of urgency. We want to bring vision to every project in a proactive and consultative way.
TECHNOLOGY OFFER Proteomics - MALDI imaging of unlabeled compounds (endogenous and exogenous), including in situ peptide fingerprinting - Peptide mass fingerprinting by protease digestion and mass spectrometry (LC-ESI-Ion Trap) - Two dimensional electrophoresis (2-DE) and 2-D western blotting - Proteome and phospho-proteome analysis: qualitative and semi-quantitative by image analysis. Cell and molecular biology - Setup, Validation and Application of: Quantitative assays (qPCR and ELISA), Qualitative and semi-quantitative assays (RT-PCR, SDS-PAGE, Western-Blot, Dot-Blot) - Setup of Pharmaco-Toxicological cell based assays: Standardized assays (LDH/MTT cytotoxicity, apoptosis, etc.), Customer-dedicated assays - Cellular and sub-cellular protein localization and protein-protein co-localization by confocal microscopy - Lab-scale recombinant protein production in bacteria, purification and testing (product qualification by activity/structure check) Bioanalytics - LC/MS/MS for analysis of small molecules and peptides (method setup, validation and application)
- ELISA for quantitative analysis of therapeutic proteins and protein biomarkers in clinical and preclinical studies (method setup, validation and application). - In vitro early ADME (Intrinsic Clearance, CYPs inhibition, Protein Binding, etc.) - Mass spectrometry analysis (MALDI TOF-TOF or LC-ESI-Ion Trap) of both low and high molecular weight compounds from synthesis or purification processes.
INTEREST IN THE ONCOLOGY VIRTUAL MATCHMAKING The participation to the Oncology virtual matchmaking event could be a way to enlarge our network and increase our competences and background in a field we are already active in. The main objective of our participation is indeed to reinforce, develop and apply our innovative services for the pharmaceutical and biotechnology industry together with new partners.
Aldevron Freiburg GmbH Freiburg, Germany - www.aldevron.com
Rapidly generate custom-made antibodies starting from cDNA (core technology), protein or peptide against a wide range of targets. Aldevron provides contract manufacturing and scientific services for antibody generation (Aldevron Freiburg), protein (Aldevron Madison) and plasmid DNA production (Aldevron Fargo). Aldevron Freiburg’s (formerly GENOVAC) focus is on the generation of custom-made antibodies directly from cDNA, without purified protein or peptide (genetic immunisation). GENOVAC genetic immunisation technology has been successfully applied for over 12 years and its custom antibodies have been referenced in over 140 publications and patents for more than 500 clients worldwide including most of the top 20 pharmaceutical companies.
TECHNOLOGY OFFER Aldevron Freiburg’s focus is on the generation of highly specific custom-made antibodies against native proteins directly from cDNA (genetic immunisation) using GENOVAC Antibody Technology. Aldevron Freiburg supports all project types from therapeutic applications to diagnostic and reagent antibodies with high success rates. Based on many years of experience, this technology has been developed to cater for all protein targets where other methods have failed (e.g. GPCRs, ion- channels). Antibodies against a wide range of targets have been successfully generated: - secreted, cell-surface, nuclear and cytosolic targets - mammalian, bacterial, viral, plant, fungal targets GENOVAC Antibody Technology is ideal to develop functional antibodies or antibodies against immuno-recessive domains or against highly conserved domains. Complementary services include conventional protein or peptide immunisation, antibody production and purification, antibody processing and characterisation.
INTEREST IN THE ONCOLOGY VIRTUAL MATCHMAKING Aldevron Freiburg will be pleased to be involved in new projects in oncology. GENOVAC Antibody Technology is a perfect tool to generate antibodies which modulate the function of a protein and could be further developed as therapeutic drugs in oncology. The technology is flexible and also allows the development of highly specific antibodies against oncology biomarkers. We hope the oncology virtual matchmaking event will give us the opportunity to discuss potential projects with scientists from a broad range of international clusters.
Allosterix Ltd Shilat, Israel -www.allosterix-pharma.com
Allosterix offers first in class, highly specific TACE\ ADAM17 inhibitor for the treatment of EGFR related cancers. Allosterix also offer a drug design service for the design of highly specific, drugable inhibitor for every enzyme. Allosterix Ltd, an Israeli drug design company founded in 2006, is focusing on the design of novel selective\ specific enzyme inhibitors. Allosterix developed the AEIDD module - a platform technology for the design of Specifins – first in class small molecules enzyme allosteric inhibitors. The platform technology is based on deep understanding of: structural biology, proteins rational design and drug- ability modifications. The platform technology applicability was demonstrated in the design of inhibitors to the industry well sought enzymes – TACE (ADAM17), BACE-1, MMP3. The Company was founded by Dr. Ariel Solomon and Mr. Omer Vunsh, and it is scientifically backed by a Nobel laureate in Chemistry, three biotech public companies CEO's and four more distinguished scientists. Allosterix solution to the specificity challenge in inhibiting enzymes: inhibiting the target enzyme via an allosteric site rather than via the active site. An allosteric site is any site on the enzyme surface, other than the active site, that modulates the enzyme activity. Allosteric sites are unique. Therefore, allosteric inhibition is inherently specific. The technology core competency lies in the capability to locate those allosteric sites in every target enzyme, and in the ability to rationally design a molecule to bind to it. Allosterix drug design technology is a structure based platform. Therefore, it is applicable in every pathology with an over expressed\ over active enzyme. The technology advantages: - Biologics selectivity & specificity is inherent in the design of the molecules - Chemo-type - In some enzymes the active site inhibitors are by nature toxic. Binding to a complete new site, offers new chemo-type opportunities - Pseudo peptides based small molecules can be bio available in most administrations, even orally - Rapid and affordable Allosterix can design an oral, specific, potent inhibitor to your target enzyme until in vivo PoC in 6-9 month.
TECHNOLOGY OFFER Allosterix offers two types of collaborations: - The design of novel inhibitors to the partner cancer target enzyme and the partner will continue the development. This includes intracellular kinases enzymes - Advancing the TACE Specifin into a drug. ADAM17\ TACE (TNF-α Converting Enzyme) TACE is the main cleaving enzyme of TGF-β which is intimately involved with EGFR cancers and of the highly potent inflammatory mediator TNF-α, which is intimately involved in autoimmune disorders. Due to its over 35 billions $/year market potential, most of the big pharmaceutical companies have pursued an anti-TACE drug for more than a decade and are still actively trying to develop a cost efficient TACE inhibitor. Allosterix has designed potent TACE inhibitors that successfully passed the in vitro (potency IC50-~100fM, serum stability, selectivity assays, allosteric inhibitions proofs), cell inhibition assay, in vivo proof of concept (RA CIA model, NMDA Glaucoma model). All of our assays are compared against the MMPs broad inhibitor, GM-6001, which reached Phase III. The results prove better activity at much lower concentrations. The inhibitors are now tested in McGill University for glaucoma, in Liege University for multiple myeloma, Glasgow University for Renal fibrosis and Charcot Marie tooth disease and hereditary peripheral neuropathies in Saint Rafael, Italy.
INTEREST IN THE ONCOLOGY VIRTUAL MATCHMAKING Allosterix has a cutting edge drug design technology. We are constantly looking for partners to develop our lead compound into drugs and approve people life. Cancer therapeutics is, no doubt, a novel goal. We are participating in a FP7 consortium and our R&D programs had a 100% grants acceptance by the Israeli CSO. We are hoping to find partners and together to receive at least 50% grant for the collaborative R&D program.
Almetis Strasbourg, France - www.almetisbio.com
Almetis design and develop anticancer metal-based molecules targeting the cell metabolism
Almetis is a French biopharmaceutical company dedicated to the discovery and the development of innovative metal-based therapeutics in oncology. Our expertise is about organometallic drugs that demonstrate anticancer properties, address the drawbacks of chemotherapies (toxicities and resistance) and constitute a new class of anticancer drugs. Our mission is to provide therapeutic solutions in clinical unmet needs via innovative treatments triggering specific mechanism of action to bypass resistance. Almetis’ drugs represent a therapeutic alternative for patients in relapse. Moreover, because of their excellent safety profile, Almetis’ drugs will improve the quality of life of patients and will provide non-toxic anticancer treatment to chronic patients. Almetis has created a pipeline gathering new chemical entities ranging from hits to preclinical candidates and is willing to develop collaborative programs with partners.
TECHNOLOGY OFFER Our technology is based on metal-based complexes having innovative anticancer features. We've demonstrated that our preclinical candidate, AL1811, is as efficient as the cisplatin among several tumour models, but is much better tolerated compared to cisplatin. This better tolerance is explained by a particular PK and bioavailbility profile of the drug limiting its accumulation. Moreover, the AL1811 is able to bypass several cisplatin resistances in vitro. Among the most interesting and promising properties are the demonstration that our ruthenium complexes use their redox potential to trigger cancer cell death. We've demonstrated the correlation between a particular range of redox potential and the optimal activity of the whole pool of complexes. Secondly, several of our leads and preclinical candidate regulate the cell metabolism. It's well known today that cancer cells have a specific metabolism compared to normal cells. Our ruthenium complexes are able to modulate some of the key metabolic pathway to induce apoptosis. The AL1811 is ready to start a preclinical regulatory development.
INTEREST IN THE ONCOLOGY VIRTUAL MATCHMAKING Almetis is interesting in partnering the development of its pipeline with complementary-skilled partners to move forward the development of our candidates. Partners proposing either an integrated development (partial or full) or a specific technology/know-how are considered.
AlphaSzenszor Inc. Barcelona, Spain - www.alphaszenszor.com
Nanotube based electronic sensors for early detection and diagnosis of cancer using biomarkers in human breath.
Alpha Szenszor Inc. was founded by Steve Lerner, Dr. Prashanth Makaram, and a team of seasoned business and technology professionals to provide cost effective, non-invasive point of care diagnostics for a variety of diseases, and related health risks. ASI has been able to demonstrate direct, digital, state of the art sensitivity (fM – pM) through proprietary semiconductor processing of CNT FETs. ASI’s ultrapure SWCNT formulations and semiconductor processes are based on IP licensed through an exclusive agreement with Nantero Inc., and are fully compatible with industry standard CMOS processing, thus allowing for very low cost, scalable products. The ASI NanoBio Chip eliminates the need for cumbersome optical fluorescence and amplification techniques typically employed in biological testing, while greatly reducing reagent costs. Said Chips are readily integrated into industry standard appliances, with applications in the infectious disease, food testing, safety and pharmacogentic fields. ASI recently closed a seed round of corporate financing, and is currently involved in a number of development programs in gas sensing, as well microfluidic delivery of proteins.
TECHNOLOGY OFFER • Label free Detection System • fM to pM Sensitivity • Cost effective, disposable cartridge - No contamination • Industry Standard Process (our CNT-FETs are routinely produced in standard microfabrication facilities). • Compact, point of care device • Eliminates optical fluorescence & costly amplification such as PCR, GC-MS • Exclusively licensed Nantero IP with over 100 patents and applications • Detection using biomarkers in human breath (no complications and special microfluidic requirements that are needed blood/urine mixtures).
INTEREST IN THE ONCOLOGY VIRTUAL MATCHMAKING ASI has a very powerful diagnostic tool for early detection of cancer using CNT-FET based sensors. Through this matchmaking event ASI is looking for collaborations from big medical and/or pharmaceutical companies in order to get into a joint venture program for early commercialization and adoption of this technology.
Argon Pharma Barcelona, Spain - www.pcb.ub.edu/homePCB/live/es/p3237.asp
ARGON PHARMA is a biotech company focused on the development of innovative therapies to combat cancer based in drug discovery of small molecules, and also in the development new technologies based on biodegradable polymers for drug delivery and diagnostic applications.
ARGON PHARMA is a biotech company created in 2008 by technology transfer from Hospital de la Santa Creu i Sant Pau de Barcelona and the University of Barcelona. Argon Pharma is established at the Barcelona Science Park with the mission to develop new innovative therapies to provide solutions to unmet medical needs in the oncology field, and also to develop new technologies for drug delivery and diagnosis to improve current therapies, increasing patient welfare and bringing real benefits to patients. Our vision is to become a global reference biotech by providing innovative solutions to current health problems of our society. Argon-Pharma supports the creativity of its committed human team to offer unique products going in with the same driving force of improving the quality of life of people.
TECHNOLOGY OFFER Currently, ARGON PHARMA focuses its efforts on two main strategic lines: The development of new drugs for orphan oncology indications, and the development of a new drug loaded biodegradable polymeric carrier for drug delivery. In the strategic line of drug discovery, Argon Pharma is currently developing new antitumor oral drugs, capable of inhibiting a mechanism of action that is associated with carcinogenic processes for a variety of oncology indications. The inhibition of this promising mechanism induces apoptosis and causes irreversible cell death of tumour cells. Our candidates are intended for oral administration, being an important competitive advantage, taking into account the current administration routes for anticancer drugs available in the market. In the strategic line of drug delivery, Argon Pharma has developed a new concept of drug-loaded biodegradable polymeric carrier. This strategy combines the efficacy of the antitumoral, with the reduced toxicity of the polymer conjugate in blood. The polymeric carrier consists in a macromolecule suitable for i.v. administration, which releases the chemotherapeutic in a solid tumour when internalizes in to the tumour cells. The strategy is being validated for CRC treatment but could be transferred to any treatment of cancers which present solid tumours. The synthetic procedures for the preparation of polymer conjugates have been optimized and the technology used offers a very easy way to get a wide range of possibilities: drug loading, drugs combination, different functionalizations. This advanced strategy has been successful on the total, controlled release of the drug at the target, with no physico-chemical alterations, and showed long stability at physiological conditions. Preliminary toxicology assays have shown the viability of the conjugates to be administered intravenously and no toxic effects of the macromolecules as well as the metabolites obtained by their degradation.
INTEREST IN THE ONCOLOGY VIRTUAL MATCHMAKING Currently our both strategic lines are focused on oncologic indications. In the strategic line of drug discovery, Argon Pharma have already identified a set of compounds that display in vitro antitumor activity in a number of cell lines, representative of different indications, opening the door for engage preclinical developments for more than one indication with several companies interested. ARGON PHARMA is actively seeking companies interested to reach an agreement to develop our compounds for other indications of interest, sharing costs during the preclinical development, and reaching agreements for the future exploitation of the products in different world markets. In the strategic line of drug delivery, ARGON PHARMA could contribute to the design of new, higher efficient, first-line treatments for cancer by designing new polymer therapeutics. And we are interested in collaborate with pharmaceutical companies to reach agreements to combine leads or candidates of interest with our technology in order to improve the compound. The optimization of cancer therapies by improving the administration of the well-known potent chemotherapeutics may prove as valuable as any of the promising new agents and even less expensive. Besides, this strategy presents the advantage to rescue some abandoned leads in oncology, despite of their efficacy, due to solubility, stability or toxicology problems and go further in the development of a new chemotherapeutic.
Astrid Research Kft Debrecen, Hungary - www.astridbio.com
Astrid is one of the largest, privately held bioinformatics companies in Europe with offices in Austria and Hungary. Our focus is data management and analysis for genomics research by providing comprehensive IT solutions for diagnostic marker and therapeutic target identification. Astrid is one of the largest, privately held bioinformatics companies in Europe. Utilizing our core competences in medicine, molecular genetics, mathematics and information technology, our focus is data management and analysis for genomics research. We sell proprietary bioinformatics products including biobank software, in-lab sequence analysis computers and advanced sequence analysis services. Our clients include academic research institutes, pharmaceutical and biotech companies, who are seeking comprehensive IT solutions for diagnostic marker and therapeutic target identification.
TECHNOLOGY OFFER 1) Malignant disease discovery software suite (http://www.astridbio.com/malignant-disease- discovery-suite.html ). The suite allows the genetic characterization of malignancies and the establishment of genetics- tailored therapeutic modalities – contributing to a better understanding of cancer biology. The suite is based on modules which can be customized according to the individual characteristics of the project. - Mutation Analysis Module: combines expression analysis, variant detection, annotation and function prediction to help the researcher identify molecular alterations behind the phenotype transformation. - Cancer Evolution Analysis Module: parallel discovery of the individual germline or somatic cell, the primary cancer and the metastasis genotype – revealing genetic alterations behind the cancer evolution sequence. 2) Biobank software for oncology genomic research project. ( www.smartbiobank.com ). The software handles samples and the related experimental, clinical, environmental and lifestyle data. It offers unparalleled convenience for the researcher – as well as external customers – in finding samples and data required by a particular project and then manage that data to provide an optimal base for answering research questions.
INTEREST IN THE ONCOLOGY VIRTUAL MATCHMAKING We are looking for clients and collaborators who can utilize our bioinformatics products and services in their oncology research.
Biognos AB Gothenburg, Sweden - www.biognos.se
Biognos AB is focused on computational screening, both ligand-based (similarity searches) and structure-based (docking) using large databases of small molecules Biognos AB is a CRO providing services in virtual screening, both structure-based and ligand-based. We are currently 3 persons working in the company and we have a computer cluster with 42 "real" cores (84 virtual processors). We work under CDA and we have no claims on IP.
TECHNOLOGY OFFER The structure based screening is performed using software like Glide or Autodock. In the ligand- based screening, where we use Topomer software and Phase shape. By these screens scaffold hopping can be achieved and patents may thus be circumvented. We offer the ligand-based screening at an attractive price of 3000-5000 euros starting from 1-5 active compounds. We currently use the emolecule library containing 5.2 mill commercially available compounds or the Zinc library with 18 mill compounds (of which 6 mill are available in stock and 12 mill are virtual).
INTEREST IN THE ONCOLOGY VIRTUAL MATCHMAKING We are interested in early drug discovery projects in the oncology field.
BioMarCare Technologies Ltd. Jerusalem, Israel - www.biomarcare.com
BioMarCare is a cancer diagnostics company developing blood and biopsy assays based on novel biomarker-panels for early detection, prognosis and monitoring of breast and colorectal malignancies.
BioMarCare is a cancer diagnostics company dedicated to the development of a cluster of high value in-vitro diagnostics (IVD) for early detection, prognosis and monitoring of cancer. The company's Multi-Biomarker Panel approach, combined with its technological and clinical expertise, promises to generate molecular, tissue or serum-based diagnostic tests with high specificity and sensitivity as well as rigorous validation, based on both novel and established cancer-specific markers. The company develops four products for breast and colorectal cancers in various stages: Breast cancer: - Breast PARpanel™- A companion diagnostics predictive test for hormone receptor positive breast cancer patients - Breast PARpanel™ - A Micro-plate blood assay based on novel breast cancer biomarkers for monitoring therapy and disease recurrence Colorectal cancer: - Colon MarCare Plex™ - A Screening test for early detection of colorectal cancer - mCRC-Strat™ – A companion diagnostics test for metastatic colorectal cancer patients
BioMarCare is located in the Jerusalem BioPark on the premises of Hadassah University Medical Center (HMC). At Israel's first medical research-oriented technology park, the company benefits from close proximity to the rich infrastructure of HMC's medical campus and the Hadassah University Hospital. Over 30 oncologists, surgical oncologists and gastroenterologists of the Hadassah medical centre are taking part in our clinical studies. BioMarCare is managed by a proven track record veteran IVD team experienced in delivering diagnostics products from idea to commercialization. The company received grants from the Israeli Chief Scientist and the bi-national US-Israel foundation BIRD. BioMarCare is a HBL (Hadasit Bio- Holdings) portfolio company. (HBL is a publicly traded subsidiary of Hadasit Ltd (TASE: HDST) - the technology transfer company of the Hadassah Hospital, Jerusalem.
TECHNOLOGY OFFER BioMarCare is using a propriety novel marker combination based on the Protease Activator Receptor (PAR) oncogenes. PAR1, a G Protein-Coupled Rreceptor (GPCR), is the first member of the mammalian PAR family consisting of four genes. PAR1 and PAR2 play a central role in breast and colorectal cancer. The over expression of PAR in blood and in tumour tissues is correlated with significantly shorter disease-free and poor prognosis. We offer to combine PAR biomarkers with additional novel or commercial markers or new technologies to generate new IVD products with increased sensitivity and specificity
INTEREST IN THE ONCOLOGY VIRTUAL MATCHMAKING BioMarCare is seeking R&D collaborations with both industry and academic partners in the field of cancer diagnostics. The company is interested in the co-development or in-licensing of novel biomarkers for cancer diagnostics assays (breast and colorectal cancers) and in new technologies. BioMarCare wish to validate and integrate new biomarkers into its current product portfolio. The company is also looking for scientific advisory board members in the field of cancer pathology and RNA markers. BioMarCare team is open to consider membership in new consortium in the field of biomarkers or oncology.
Biomotif AB Stockholm, Sweden - www.biomotif.com
Biomotif technology for: Conformational Epitope Mapping, Binding Site/Mode-of-action studies and Compound-Fishing-Epitope Imprinting affinity capture in the liquid phase. Biomotif develops new technology for analysis of complex biological samples. We have developed a new unique multifunctional HX-IA Instrument for Mass Spectrometry. We work with "Scientific Collaboration Partners". Biomotif will perform "Fee for service" analysis for the Pharmaceutical and Biotech industry: H/D Exchange "Mode of Action" analysis including binding site study and conformational Epitope Mapping.
TECHNOLOGY OFFER With our technology we can study molecular interactions such as binding site studies, "mode-of- action" analysis (Epitope Mapping) and other H/D Exchange assays. A potential drug candidate can bind to the target with different affinity depending on the conformation of the biomarker. We are also developing other new technologies such as "Findtheneedleinthehaystack" for on-line separation of proteins depending on the iso-electric point. Compound Fishing-Epitope imprinting technology for enrichment and capture of specific compound classes from a complex matrix such as for example: steroids, hormones, vitamin D, citrulinated peptides and more.
INTEREST IN THE ONCOLOGY VIRTUAL MATCHMAKING To find collaboration partners in research.
ChemCon GmbH Freiburg, Germany - www.chemcon.com
ChemCon is the expert for inorganic and organic chemical R&D as well as small scale GMP API production, including high potents and legally controlled drugs.
ChemCon is a global service partner of the pharmaceutical and biotechnological industries. Our wide range of services links drug discovery and medicinal chemistry with commercial production of APIs up to multi kilo quantities. We are specialized on small molecule chemistry – organic and inorganic. Based around chemical development on various stages of drug development we offer an all-in-one- hand service for our customers including full analytical support, complete documentation and quality management. Our highly qualified, service oriented team is the perfect partner to complete your project in a timely and quality oriented fashion.
TECHNOLOGY OFFER HPAPI containment suites and equipment allow safe operation within the limits of Safebridge class 3 Employees are well trained for secure approach strict guidelines through specific SOPs (standard operation procedures) our dedicated equipment strategy prevents even the slightest risk of cross- contamination. All analytical equipment usually required for development and API release like HPLC, LC-MS, GC, FT-IR, opt. rotation, titrations, MP, multi-nuclear NMR, UV-VIS, etc. is available in-house microbiological testing for the release of injectable API´s.
INTEREST IN THE ONCOLOGY VIRTUAL MATCHMAKING In reaction to the constantly growing worldwide demand of cytotoxic HPAPIs, ChemCon is expanding its manufacturing capabilities for HPAPIs in multi-kilogram quantities by containment down to 0.1 μg/m3 OEL. The new multi-purpose isolator train is currently being installed at the company site in Freiburg, Germany. Thus ChemCon is in the perfect position to offer custom manufacturing of even the most active cytotoxic ingredients.
EPHORAN MULTI IMAGING SOLUTIONS Turin, Italy -www.ephoran-mis.com
EPHORAN Multi-Imaging Solutions, a CRO providing imaging expertise and knowledge for the application of imaging technologies in pre-clinical drug research and development.
EPHORAN Multi-Imaging Solutions is a Contract Research Organization providing imaging expertise and knowledge to study, develop and promote the application of imaging technologies in preclinical drug research and development. EPHORAN provides the opportunity to apply a translational pharmacological approach in drug R&D, evaluating in animal models a molecular-based proof of biological activity and mechanism of action, and translating it into the clinical setting. All the techniques extensively employed in the clinical setting (e.g. PET, CT, SPECT, MRI, US and in Optical Imaging, both visible light and near infra red) are available. EPHORAN fosters the development of diagnostic tools, reagents and methodologies for experimental imaging and makes the drug development faster and more cost effective. Pharmaceutical companies will take advantage from its preclinical imaging technologies to carry on more effectively their R&D projects in different therapeutic such as oncology, cardiovascular and CNS. The application of imaging techniques allows a significant reduction of the time-to-market of novel compounds. Other users that will benefit from access to Ephoran’s services are researchers from academic and research institution. Specialities: MRI Imaging services, PET/SPECT imaging services, CT imaging services, ultrasound and optical imaging services, customer labelling with probes for MRI, CT, US and OI and contrast agents services for preclinical research.
TECHNOLOGY OFFER EPHORAN is uniquely positioned in pre-clinical and clinical imaging allowing serial/longitudinal imaging experiments and during, pharmacology and toxicology animal studies. EPHORAN’s services for pre-clinical imaging should provide access to MRI with 0.2 (Esaote), 3 and 7T imagers, µPET/SPECT/CT, High Frequency Ultrasound and Bioluminescence and Fluorescence imagers. Contrast agents for MRI, CT and US, both those already used in clinical setting and those specific for pre-clinical imaging, are available. The in-house availability of a cyclotron for industrial production of research PET tracers provides both labelled candidates and custom labelling of candidates molecules for pre-clinical studies (18 F, 68Ga, 111In, 177 Lu, 99Tc). The availability of state-of-the-art instruments allows to perform different kinds of experiments: - Oncology: Imaging on transgenic and xenografts models (tumour metabolism, proliferation and growth, apoptosis , angiogenesis, drug efficacy evaluation) - Cardiovascular pathology: Imaging on transgenic and induced pathological models - Cerebral pathology: Imaging on induced pathological models (stroke, glioma , degenerative pathologies) - Inflammation: Imaging on induced pathological models (arthritis, macrophage detection) - Validation of new biomarkers of pharmacological activity as predictors of drug response in the clinical setting (novel drug delivery and gene therapy approaches).
More on: http://www.ephoran-mis.com/ and http://www.linkedin.com/company/ephoran-multi- imaging-solutions/products
INTEREST IN THE ONCOLOGY VIRTUAL MATCHMAKING The Company is engaged in development of imaging services and Pharma and Toxicology services and in their promotion and application in preclinical drug research and development covering different therapeutic or diagnostic areas and oncology is one of the most important. The selection of this therapeutic/diagnostic area is based on a number of factors: - It is the main area of ongoing drug research and development - it is the main area where Ephoran has its experience in term of imaging services - it is the main therapeutic area where some relevant biomarkers are already known, simplifying the process of identifying relevant and more appropriate imaging technologies to be applied both in preclinical and in clinical settings. Ephoran’s commercial strategy has a pronounced focus on the European market and the objective is to commercialize its services through own resources and in long term in combination with one or several partners. The participation to the Oncology virtual matchmaking event will allow the promotion of Ephoran’s services and expand the commercialization of its technology and services in the European marketplace through direct contact with possible customer and through partnership with CROs and exclusive collaboration with Pharma industries.
GenIbet Biopharmaceuticals Lisbon, Portugal - www.genibet.com
GenIbet is a GMP manufacturing facility for Advanced Therapies (cell therapy, stem cells and gene therapy), as well as for bacterial products, in totally segregated and dedicated production areas. GenIbet is a GMP manufacturing facility for Advanced Therapies (cell therapy, stem cells and gene therapy), as well as for bacterial products, in totally segregated and dedicated production areas. We produce mostly for pre-clinical and phases I and II. We are a spin off from IBET, a Research Institute that is well known for its work of research and development in these fields. Thus, IBET complements our production capabilities with excellent development expertise. Together, we are working with research and clinical groups in process development and GMP production of their products. Our list of services is:
TECHNOLOGY OFFER - Biopharmaceutical Process Development (together with iBET) - cGMP Bulk Biopharmaceutical Production - cGMP Master and Working Cell Bank Production - cGMP Master and Working Viral Seed Stock - cGMP Cell and Gene Therapy Production - Quality Control/Quality Assurance Services - Fill and Finish - Support Dossier Filing with different Regulatory Authorities
INTEREST IN THE ONCOLOGY VIRTUAL MATCHMAKING GenIbet, a cGMP Contract Manufacturer, together with its main shareholder, IBET, can make a difference in projects that need to move from the research labs and research scale to the GMP production.
iBET - Instituto de Biologia Experimental e Tecnológica Lisbon, Portugal - www.ibet.pt
IBET is a private not for profit Portuguese biotechnology research organization created in 1989, where science and technology are used together to ensure the translational application of competences from early stage discovery to final production and processes. iBET is a private not for profit Portuguese biotechnology research organization created in 1989, located in Oeiras, Portugal. iBET interfaces between academic institutions and the economy while creating and organizing autonomous knowledge and expertise. Science and technology at IBET are used to ensure the translational application of competences from early stage discovery to final production and processes. iBET fosters the competitiveness of partners and customers, by creating wealth out of knowledge in Chemistry, Biochemistry and Biology. The main areas of iBET are health-pharma, agro-industry, forestry, agriculture and the environment. iBET activities are focused on: biopharmaceuticals and novel therapies; protein stability, structures and drug design; water energy and the environment; food and wellness; agro-forestry; pilot-plant services and analytical services. iBET fulfils the requirements for being classified as SME participant in FP7, according to the Commission Recommendation 2003/361/EC in the version of 6 May 2003. To the exception of ‘Research for the benefit of SMEs’ of the Specific Programme Capacities, where it can only participate as a research provider (RTD performer). Our research capacities, infrastructure and highly qualified services: IBET runs 16 laboratories (70m2 each), owns an adjacent bio pilot plant of 2000 m2. For analytical services, we are GLP certified for already 20 years. IBET offers high quality analytical, biochemical, microbiological and field trial services within its Good Laboratory Practices (GLP) certified laboratories and activities. Develop better on this Consultancy for Biotechnological Industry Processes. Consulting expertise is offered to companies developing biochemical engineering and biotechnological processes. Our services can be particularly useful for companies aiming to become established in Portugal or to enter the European market through Portugal. Collaboration with industry Sovena, SUMOL+COMPAL, Tecnimede, Bayer, Micromet, Merk Serono, Cevec, Merck & Co, Astra Zeneca, Centocor, Apceth, Sartorius-Stedim, Genethon, Alloskys, Cellartis, Novartis, Glycofi, Lonza, LETI, PBS.
TECHNOLOGY OFFER • Recombinant proteins including monoclonal antibodies Vectors for gene therapy development of 3D in vitro cancer models by conjugating bioreactor technology and multicellular aggregate approaches. • In vitro models for prediction of drug absorption and metabolism.Differentiated Caco-2 cell monolayers express most drug-metabolizing enzymes and transporters but fail to express carboxylesterases (CES) at the same relative level that they can be encountered in the
intestine. iBEt is developing, an improved Caco-2 model that can express those enzymes particularly CES 2 - expressed in human intestine, an increasingly important enzyme in anti- cancer combined therapies for the treatment of different pathologies like colon adenocarcinoma and malignant glioma.Know-how in modulation of the absorption of bioactive compounds and drug-drug interactions biological activities for fullerenes and derivatives have been claimed. However fullerenes have low water solubility making formulation and biological testing difficult, precluding activity tests in physiologically related media. We investigate ways to overcome this problem, the antioxidant potential, toxicity and proliferative effects, and the ability of fullerenes and conjugates to cross biological membranes.Co-administration of different drugs or dietary supplements can affect the therapeutic outcome of drugs. We study the effect that some dietary supplement formulations may have in the metabolism of prescription drugs.
INTEREST IN THE ONCOLOGY VIRTUAL MATCHMAKING As a participant what does iBET look for? Among iBEt focus areas are biopharmaceuticals, novel therapies and drug design, and we are looking for strengthening and diversifying our projects, as well as, expertises, in the area of oncology. This initiative is therefore an excellent opportunity to have access to top-notch research and bring new venues for collaboration. As a participant what can IBET bring? Other companies can benefit from iBET competences, technologies and know-how in drug delivery systems and biopharmaceuticals from discovery, production and characterization; biochemical engineering tools, as well as, pharmacokinetics and biopharmaceutical analysis. We have extensive experience in working in consortium. Complementing iBET expertises, we work in direct connection with GenIbet, a contact manufacturing organization in the area of biopharmaceuticals.
IDD Therapeutics Ltd. Nazareth, Israel - www.idd-therapeutics.com
IDD Therapeutics is engaged in development of anticancer drugs based on intelligent learning engine which enables design of multifunctional small molecules, for various potential biological targets for cancer, exhibiting potential superior safety and efficacy profiles compared to current therapies for a wide range of indications.
IDD Therapeutics is an Israeli start-up company committed to designing, developing and commercializing innovative pharmaceuticals for cancer. The company was founded in 2010 by Dr. Anwar Rayan, an experienced researcher in drug discovery and development process. IDD is supported by the Office of the Chief Scientists and operates within the NGT incubator in Nazareth, Israel. The Company bases its drug discovery and development on the Intelligent Learning Engine (ILE), a powerful bio-informatics platform invented by Dr. Rayan, which enables rapid functional modeling throughout the entire process of drug development, cost effective and significant shortening the development process. This platform is protected by a patent application. The technology was used to select a set of drug candidates, multifunctional small molecules inhibitors, for various potential biological targets for anti-cancer pharmaceuticals. The Intellectual Property (IP) is one of IDD Therapeutics major assets: - AntiCancer Drugs: Derivatives of Taxol and Closely Related Compounds –WO/2009/090614 (bi-functional drug candidates – microtubules and MMP-2). National patent applications are pending. - ILE: system and methods for performing a screening process - PCT filed Jan 24, 2009 WO/2009/090613. IDD Therapeutics plans to file additional patent applications related to other drug candidates in its pipeline. The company employs professional development team headed by Dr. Rachel Philosof- Oppenheimer, proven experienced in R&D project management, marketing and business development in the pharma field. IDD therapeutics is part of consortium of multiple myeloma shared with two other biotech companies, Pepticom Ltd and Genearrest Ltd.
TECHNOLOGY OFFER IDD Therapeutics is focusing on the design and development of novel bi-functional drug candidates, exhibiting potential superior safety and efficacy profiles compared to current therapies for a wide range of cancer indications. By applying ILE, IDD Therapeutics was able to select a set of candidate molecules of which MDL-1100 is the most promising. The company's first lead compound, MDL- 1100, is a novel synthetic small molecule for the treatment of solid tumours and metastasis. Initial proof-of-concept experiments have been conducted for both our lead compounds, MDL-1100, and a widely used chemotherapy agent, which served as "control" for comparison. In preliminary studies, a significant in vitro cytotoxic effect of MDL-1100 was demonstrated in various human cancerous cell lines. Our lead compound exhibited order of magnitude lower toxicity on human normal muscle cells compared to the positive control. A toxicology study in mice showed a favourable safety profile vs. the clinical standard. The in vivo orthotopic model in mice indicated significant inhibition of tumour growth and regression in tumour volume following treatment with MDL-1100. In vitro hERG channel assay revealed no effect of MDL-1100 on cardiac hERG channels at concentrations ranging from 10- 100uM. Stimulated by the very promising preliminary results, IDD Therapeutics is presently engaged in a systematic development process, FDA regulation-oriented pre-clinical studies of MDL-1100 consisting CMC, advanced toxicology, efficacy, MOA and pharmacokinetics. In parallel, we are using our powerful platform to design and develop a diversified pipeline consisting of additional drug candidates currently under different stage of development.
INTEREST IN THE ONCOLOGY VIRTUAL MATCHMAKING IDD Therapeutics is seeking US$2M to support MDL-1100 preclinical studies completion and the commencement of Phase I/II trials. The company is currently interested in international partnering opportunities; investors and strategic partner for a collaboration involving an upfront payment, milestones and royalties, to enable its products to realize their full potential.
im3D S.p.A. Turin, Italy - www.i-m3d.com im3D is an Italian company which designs, develops and markets medical workstations for supporting radiologists in the early diagnosis of cancer. Since 2010, im3D offers screening and corporate prevention services as well. im3D S.p.A. is an Italian company established in 2004, which designs, develops, produces and markets medical devices intended for early diagnosis in medical imaging. Its mission is to research and develop high-tech innovative solutions in medical imaging for cancer prevention. im3D's products use the most advanced technologies, especially in the field of CAD (Computer Aided Detection), which are based on proprietary calculation algorithms and methodologies developed through many years of experience in scientific, clinical and technical research. Its vocation is to work alongside doctors and researchers to get to understand their needs, and collaborate with them in creating new and more powerful investigative and diagnostic instruments. Instruments which are less invasive, as well as more flexible, more reliable and simpler to use. In a word: more advanced. To reach this objective, and from the moment it was established, im3D S.p.A. has chosen to operate constantly to the highest quality standards and to aim for continuous improvement: both inside the company when researching and developing new solutions, and externally, in ensuring that customers are fully satisfied
TECHNOLOGY OFFER CAD COLON is a CAD (Computer Aided Detection) medical device which provides support in colon- rectal cancer diagnoses. The platform was conceived for the analysis of Virtual Colonoscopy exams on CT scans. CAD COLON can assist the Radiologist in his/her clinical activity by increasing diagnostic accuracy and reducing reading time. CAD COLON can also be used as a learning tool for the less experienced Radiologist. CAD COLON is also the chosen support for the world’s first trial screening (the Protéus Project, currently active on a total population of 26,000 asymptomatic medium risk patients) based on the use of CAD as a potentially primary reader in colon-rectal cancer screening. CAD BREAST DTS is a medical device for the diagnosis of breast cancer. The system is conceived for the analysis of digital mammography exams and tomosynthesis exams. The CAD BREAST DTS workstation provides a powerful graphic user interface to view images and a set of simple and intuitive commands. CAD BREAST DTS proficiently assists the specialist in reading mammography exams in a clinical context thanks to its versatility, integration and adaptability. CAD BREAST DTS integrates the first 3D mammography CAD for tomosynthesis images, dedicated to micro- calcifications and masses
INTEREST IN THE ONCOLOGY VIRTUAL MATCHMAKING im3D is strongly interested to get in touch with European enterprises in order to know and share experiences that could lead to collaborations in innovative products and services. im3D is interested in collaborating in terms of R&D projects, clinical validation studies, products/services promotion, etc.
Intelligent Pharma Heidelberg, Germany - www.intelligentpharma.com Other locations: Barcelona, London
Intelligent Pharma is a service company specialized in computational chemistry and molecular modeling applied to drug discovery and development with experience in oncology research projects. Intelligent Pharma is a company specialized in computational chemistry and molecular modeling applied to drug discovery and development. Using our in-house developed technologies, we offer computer-assisted drug design to discover, enhance and study drugs and drug candidates. Intelligent Pharma has a wide portfolio of computational technologies in the field of medicinal chemistry developed through the company's internal research. Thanks to these technologies, Intelligent Pharma offers a wide range of services in the field of computer-aided drug discovery and molecular modeling. Our expertise: Identification of new active compounds, determination of new inhibitors, computer-aided Hit to Lead, lead optimization, determination of mechanisms of action, ADME/Tox predictions, drug reprofiling, etc.
TECHNOLOGY OFFER We carry out fully integrated customized research projects to find solutions for our client’s needs. Our pipeline of technologies includes: - HERCULES, Ligand-based virtual screening solution. HERCULES is a computational tool which identifies non-structural analogs of a reference compound with similar biological activity and with a completely different chemical structure. - SELENE, Receptor-based virtual screening solution. SELENE is a computational tool which identifies active molecules with the ability to bind a receptor. - CHIRON, Computer-aided hit to lead optimization. CHIRON is a technology for Hit optimization which determines the compounds with the desired properties while drastically reducing experimental & synthesis efforts. - MEDEA A data mining solution for medicinal chemistry. MEDEA is a data mining solution for the identification of biological patterns and the prediction of biological properties.
INTEREST IN THE ONCOLOGY VIRTUAL MATCHMAKING During the last 5 years, we have carried out more than 100 research projects in different areas. We have expertise in the oncology field in hit identification, determination of mechanism of action, hit to lead, etc. We are developing projects as services but we also find partners to co-develop projects to validate our new technologies. We would appreciate to contact companies in early drug discovery to discuss how we could collaborate together.
I-SEE Turin, Italy - www.i-seecomputing.com
Internet-Simulation Evaluation Envision is a high tech start-up company operating in the field of Monte Carlo simulations and their application in oncologic field. Internet-Simulation Evaluation Envision is a high tech start-up company operating in the field of Monte Carlo simulations. I-See is an academic spinoff of the University of Turin. Our expertise are result of 10 years experience in the field of simulations and their application in oncologic field within the department of experimental physics and the national institute of nuclear physics in Turin. Our solution is based on a `Monte Carlo simulations’ that is a powerful technique for accurate calculations and can be adopted for a large variety of scenarios in physics and radiation biology. This methodology is largely used in scientific research and it is the most accurate in approaching the physics reality of the problems, since it is based on the principle of stochasticity and randomness in analogy with nature laws. Monte Carlo simulations require huge computational resources and expertise which cannot be managed always by the final user. I-See wants to make accessible such advanced service to the customer, proposing an innovative modality of use. The proposed service consists in providing personalized softwares developed on Monte Carlo techniques, opportunely built to meet the specific requirements of the customer, combined to a computational model similar to the cloud-computing approach, based on the de-localization of the computing resources, and adopting a parallelized HPC architecture to speed up the calculation. For the moment I-See provides software applications and services to users mainly in the field of medical physics for: - Advanced radiation therapy - Radiation biology - Radio-protection I-See team will involve soon different professional figures to adapt itself to the market requirements and the customers claims, involving other specialized and interdisciplinary experts (physicists, chemists, biologists, computer scientist, physicians) to enlarge also the competence and the portfolio of fields of interest, where the I-See concept, which is to put together expertise, services, computing resources and Monte Carlo simulations, presents the optimal solution to the requirements of those activities.
TECHNOLOGY OFFER The main innovative aspect is putting together interdisciplinary expertise (MC simulation, supercomputing, effect of radiation on matter, biological response to radiation…..) in one solution, offering the final user an easy and efficient tool for its required analysis, with user friendly remote applications. We are already working with advanced oncologic centre, for the characterization of the effect of radiation, contributing first in the design phase of the treatment room components and the monitoring devices used there, and for the commissioning phase to store all the necessary data for the treatment, and finally for the quality assurance of treatment planning. All our products are customized according the requirements of the centre. All our products have to be updated continuously following the latest news in matter of physical and radiobiological models used in the field of radiation effect.
INTEREST IN THE ONCOLOGY VIRTUAL MATCHMAKING We are looking for: - Research institutes and companies interested in R&D of new and innovative products created for a better answering to the market need in the field of advanced oncology technology. We are operating at the international level. - Investors for acceleration of the development of new products and R&D, for the internationalization and speed up of the initiative of the firm and scale faster. - Distribution partner and intermediaries to join the international market - Companies and corporations embracing the open innovation paradigm to boost their development potential.
LEITAT - Biomed Division Barcelona, Spain - www.leitat.org
Leitat’s Biomed Division discovers new therapeutic drugs and new diagnosis tools by means of its specialized technological platforms and strong expertise in oncology. The Biomed Division also fosters collaborations, partnerships and services with leading pharma and biotech companies and institutions.
The expertise of Biomed Division members rely on more than 15 years of experience in basic and applied oncologic research in the pharmaceutical industry arena. Some of the targets and drug candidates previously developed by our scientists are currently in phase III, II, and I oncologic clinical trials. Actually, our therapeutic focus is cancer in its broad sense and therefore represented by any of the three compartments: tumour (tumoural cells), vascular (activated endothelial cells), stromal (support cells), and also including cancer stem cells and metastatic dissemination.
TECHNOLOGY OFFER Therapy: The principal investigation activity of the team involves the identification of new oncology therapeutic targets, the validation of these targets, the generation of therapeutic agents (specially monoclonal antibodies, Mabs), the study of its mechanisms of action, and the functional characterization of these agents (monoclonals and chemical compounds) in validated in vitro & in vivo models of both tumour progression and tumour angiogenesis. Final aim is to deliver these innovative drugs as clinical development candidates (preclinical proof of principle - PoP). Diagnosis: An additional goal includes the design and characterization of front-edge reagents, tools and devices for diagnosis, prognosis and monitoring of cancer and other diseases. Biomed Division goal is to position itself as a reference centre in theragnosis. Specialized bio-services: We provide consultancy and assessment services in drug discovery programs. Based on our oncologic profiling resources we are able to provide the basis to identify unrevealed indications for known leads. Additional R&D tailored research for customers and collaborations include the next technological platforms: - In vitro cell models (proliferation, viability, apoptosis, nanotox, migration, adhesion, angiogenesis, etc) - In vivo animal models (singenic & xenogenic, ectopic & orthotopic primary tumour experimental & spontaneous metastasis, angiogenesis, non-invasive imaging) - Preclinical histology (paraffin embedding, sectioning and standard staining) - Generation of monoclonal and polyclonal antibodies for basic research, diagnosis and therapy. Monoclonal antibody engineering: chimeric, humanized and biosimilars
INTEREST IN THE ONCOLOGY VIRTUAL MATCHMAKING
At the LEITAT's Biomed Division we believe in the need for the collaboration between different institutions to advance research at all levels, so we look for synergies and foster collaborative initiatives to challenge innovative biomedical research projects. We also consider partnering pre- clinical research & development as joint initiation or co-development projects for either new or validated targets.
LipoCure Ltd Jerusalem, Israel - web site in construction
Lipocure is an early stage pharmaceutical company with strong IP, developing; Injectable long circulating corticosteroid liposomes for acute inflammatory diseases, long circulating chemotherapy liposomes for various cancers and second generation long circulation Doxorubicin liposomes. Lipocure has established small aseptic production facility for nano-drugs production and plan to start first human study on 2012. LipoCure is an early-stage R&D bio-pharmaceutical company developing passively targeted liposomal drugs. Although a young start-up, LipoCure utilizes the vast experience gained by the laboratory of Prof. Yechezkel Barenholz in co-developing the anti cancer drug Doxil®, the first FDA-approved nano- drug and also liposomal drug. Doxil is considered one of the gold standards of drug delivery systems (DDS). Long-circulating nano-liposomes loaded with anti-inflammatory glucocorticoids or anticancer drugs at high drug concentration per liposome (like Doxil®) provide passively targeted delivery of the drugs to the diseased tissue combined with reduced side effects and improved therapeutic efficacy. Our pipeline includes projects close to “first in human” and projects in preclinical stages. LipoCure intends to commence Phase I clinical testing by the beginning of 2012.
TECHNOLOGY OFFER Long-circulating nano-liposomes loaded with therapeutic levels of drugs which, due to their nano size, long circulation time, unique drug loading approach, and the special micro-anatomy of inflammatory and tumour blood vessels, cause the drug carrier to preferentially extravasate into the diseased tissue and release the anti-inflammatory or chemotherapeutic drugs there. LipoCure Ltd has a small formulation hub for sterile and aseptic filling of small scale ore-clinical and Phase I clinical samples
INTEREST IN THE ONCOLOGY VIRTUAL MATCHMAKING LipoCure Ltd looking for joint-ventures and co-development where LipoCure will encapsulate in liposomes new anti-cancer drugs and also will produce small scale production of nano-drugs dosage forms under aseptic conditions.
Pathology Diagnostics Cambridge, UK - www.pathologydiagnostics.com
Pathology Diagnostics Ltd is an independent GCLP accredited histopathology CRO delivering high quality tissue laboratory and diagnostics services to industry Research & Development scientists engaged in drug and biomarker development. Pathology Diagnostics Ltd. (www.pathologydiagnostics.com) is an award-winning GCLP-accredited laboratory in Cambridge UK providing tissue laboratory/diagnostic services for UK and international clients engaged in preclinical studies and Phase I-III clinical trials; biomarker testing and companion diagnostic development. We work with the following clients: • Industry R&D companies (pharmaceutical, CRO and biotechnology): protein biomarker assay development and analytical validation in preclinical discovery models and clinical trials; clinical validation and evaluation of tissue samples; expert diagnostic readout of tissue biomarkers including image analysis; development and testing of tissue based companion diagnostics. • Healthcare providers: clinical validation and evaluation of tissue samples for companion diagnostic testing; testing and evaluation of tissue protein biomarkers by IHC for patient stratification prior to treatment. Over the last few years, we have performed tissue biomarker and laboratory/diagnostics analyses on approximately 40,000 patient samples per year from a wide variety of studies from early discovery through to clinical trials and in a wide variety of disease areas, mainly oncology (breast, NSCLC, colorectal, prostate, gastric, ovarian, H&N, pancreatic, melanoma, renal, CNS) but also cardiovascular, metabolic and bone medicine.
TECHNOLOGY OFFER Our team of expert medical/veterinary pathologists and trained scientists with over 120 years' combined experience of medical diagnostics and scientific research provides a unique breadth of scientific and medical consulting/diagnostics expertise. We pride ourselves in understanding your project needs and providing advice and high quality consistent reliable results on time, every time, enabling you to make informed data-driven decisions on the likely success of your companion diagnostic programmes. When working with Pathology Diagnostics Ltd., you can also expect a friendly, client orientated approach, complete confidentiality, a fair and competitive price. Pathology Diagnostics Ltd. has won the following awards: • 2010 UK Medilink Awards - finalists • 2009 ERBI Best Biotech/Medtech Start Up Award • 2008 EW Eastern Region Science & Technology award
We offer the following technologies to deliver high quality tissue validation and biomarker data to our clients: • High resolution image capture and tissue morphometric analyses using digital image capture and semi-/fully automated image analysis packages. We have experience of quantitative
image analysis on a wide variety of clinical and preclinical studies in oncology, cardiovascular, metabolic and bone pathology • Tissue laboratory processing of fixed tissue samples; paraffin wax embedding; H&E and specialised histological stains and techniques • TMA manufacture and analysis – including donor block H&E review, core area selection, automated arraying, H&E and antigenicity staining of TMA block, TMA array mapping and tissue validation/diagnostic analysis • immunohistochemistry assay development validation and testing:
We have extensive experience in the analysis of proteins in multiple disease associated pathways including signalling pathways, DNA repair pathways and cell surface receptors. Types of IHC markers evaluated: a. Cell surface receptors, including lymphocyte cell surface receptors, both total and phosphorylated forms b. Proliferation markers c. Cell death/apoptosis markers d. Markers of invasion/metastasis e. Cell cycle/chromatin remodelling markers f. DNA damage sensing and repair markers g. Signal transduction pathway markers, total and phosphorylated h. Other markers used in clinical diagnosis
INTEREST IN THE ONCOLOGY VIRTUAL MATCHMAKING The ABC Europe Virtual Matchmaking Event is a great opportunity for Pathology Diagnostics Ltd. to engage with companies in continental Europe who are interested in our technologies. We would like to establish cross-border collaborations and form lasting partnerships by delivering innovative tissue diagnostics and laboratory techniques for biomarker testing for stratified medicine and tissue analyses for oncology clinical trials. We aim to add value to our clients’ development programmes for novel molecularly targeted drugs and companion diagnostics, thus speeding up the time to market and reducing R&D development costs.
We believe our technologies and experience would be very beneficial to small and medium sized organisations who may not necessarily have the in-house expertise to perform their own tissue based testing of drugs and biomarkers, who are looking to partner with a team who can provide the necessary project management skills as well as the technological and medical diagnostic expertise to deliver high quality accurate and reliable results to regulatory standards. We also have experience of working with major global pharmaceutical and CROs and are able to bring the same high standards of excellence required by these organisations to a more tailored approach for the smaller client organisations.
PROCELLTECH SRL Turin, Italy -www.procelltech.net
Procelltech's is a service provider for GMP-compliant Quality Control assays and for biological assays to characterize compounds in R&D phases.
Procelltech is focused on: - Regenerative Medicine - Quality Control Assays on cellular products for advanced therapies - GMP Production - Quality Control Assays for Consultancy for biotech products, GMP consultancy services design of GMP facilities, documentation drafting for GMP authorization Preclinical (R&D) and Phase I-IV clinical trials set-up and development of ex vivo and/or in vitro assays to study compound mechanism of action. Procelltech activities are compliant to the Good Manufacturing Practice (cGMP). Procelltech facilities have been inspected by Agenzia Italiana del Farmaco (AIFA) to be authorized to conduct Quality Control (QC) assays and release of product batches. In Procelltech are present: one Qualified Person, one Manager Responsible for QC activities, Quality Assurance Unit. The pillars of Procelltech Quality System are the following: - Risk Assessment and Validation Master Plan - Qualified and trained personnel - Adequate premises and equipments - Written procedures for all the activities and processes - Documentation management - Self inspections
TECHNOLOGY OFFER GMP Quality Control Assays for biotech and advanced therapies products, Impurity Sterility (Rapid, 7 day test), Impurity Endotoxin level detection (LAL test), Impurity Mycoplasma detection (NAT, qPCR, Rapid), Impurity Viral detection (NAT, qPCR and IVVT), Identity DNA sequencing and DNA profiling Identity FACS staining (IPT, up to 8 colours), Identity Isoenzyme test Potency, Karyotyping (G- banding), Potency CFU-F assay, Potency Cell count and Viability, Assays for Proof of Concepts (POC) Proof of Biological Activity (PoBA), Mechanism of Action (MoA) evaluation - Cell culture and assays according to custom requests - Functional assays (cytokine, chemokine, soluble factor release) - Genetic expression analysis (qPCR)
All assays can be performed with whole blood, PBMC, stabilized and primary cell lines incubated with appropriate stimuli and with different doses of compound. All the experimental settings can be tailored according to specific needing of the client Techniques, Cell and Molecular Biology Set-up, Validation and Application of different cell-based assays: - Viability and cell proliferation - Apoptosis - Cell cycle analysis
- Immunophenotyping (up to 8 colours) - CRS - Genetic expression analysis (qPCR) - Sequencing - ELISA
INTEREST IN THE ONCOLOGY VIRTUAL MATCHMAKING Procelltech services could help in development of new therapies for oncology.
Promec Elettronica SrL Turin, Italy -www.promecelettronica.it
Design & Production of "Electronical Devices"
TECHNOLOGY OFFER In the “Electro-Medical Equipments Sector”, Promec designed and produced the following products: - an innovative “Digital Current Amplifier” (current coil injection) for magnetic resonance equipments - a “Switching Power Supply” for magnetic resonance equipments - a “Switching Power Supply” for the magnetic resonance medical-crib - a “Portable Switching Power Supply” for electrocardiogram portable equipments - a “Special Small UPS” for portable air ventilation systems.
INTEREST IN THE ONCOLOGY VIRTUAL MATCHMAKING The possibility to find partners in order to develop and to produce new electromedical devices.
ProQinase GmbH Freiburg, Germany - www.ProQinase.com
By offering active recombinant kinases, biochemical kinase screenings, various cell-based assays and in vivo models, ProQinase is a leading preclinical service provider dedicated to support clients from academia, pharmaceutical and biotech industries in the development of novel therapies for cancer treatment The Solution Provider for Drug Discovery in Oncology, ProQinase is a leading preclinical service company dedicated to support pharmaceutical and biotech clients in the development of novel therapies for cancer treatment. The company has a long-standing scientific experience in the fields of protein kinase and tumour angiogenesis research. Currently 223 in-house produced catalytically active protein kinases and 10 kinase substrates are offered for sale and more than 353 protein kinases are available for biochemical kinase assay services (HTS, selectivity profiling and IC50 determination). Hits derived from biochemical kinase assays can be further characterized at ProQinase in cellular phosphorylation assays and in various functional cellular assays (migration assay, soft agar assay, angiogenesis assay). For further evaluation of lead compounds ProQinase offers various in vivo testing services including subcutaneous (xenograft) models, orthotopic tumour models with in vivo and ex vivo bioluminescence analysis and a unique angiogenesis assay. In addition, ProQinase provides custom-tailored solutions as support for cancer drug discovery projects.
TECHNOLOGY OFFER 1) Recombinant proteins ( http://proqinase.com/content/view/153 ) ProQinase offers one of the largest collections of recombinant protein kinases for biochemical activity assays and recombinant generic protein substrates validated for more than 300 different kinase assays. 2) Kinase screening services ( http://proqinase.com/content/view/27 ) ProQinase offers flexible biochemical kinase assay services, i.e. (i) the number of test compounds, (ii) the kinase panel and (iii) the number of data points per test compound may be freely determined. Typical services are profiling projects with a few compounds or high-throughput screening of large compound libraries. 3) Cellular assay services ( http://www.proqinase.com/content/view/28 ) ProQinase offers (i) cellular phosphorylation assays to assess the inhibitory effect of compounds on a given kinase in a cellular background, (ii) cellular migration assays on various cell lines, (iii) spheroid- based cellular angiogenesis assay to evaluate the pro-/anti-angiogenic potential of compounds and (iv) soft agar assays for testing the effect of compounds on anchorage independent growth in up to 60 human cancer cell lines. 4) In Vivo Testing Services ( http://www.proqinase.com/content/view/32 ) Besides a Spheroid-Based in vivo Angiogenesis Assay allowing to evaluate the efficacy of small molecule test compounds or antibodies directed against a human, endothelial cell-specific target,
ProQinase offers various subcutaneous and orthotopic in vivo tumour models to perform efficacy studies.
INTEREST IN THE ONCOLOGY VIRTUAL MATCHMAKING ProQinase's scientist have a long-lasting experience in oncology-, kinase- and angiogenesis-related research and thus are highly qualified to support R&D approaches of the pharmaceutical and biotech industry or academic institutions. Our aim is to identify new customers within the participating companies that might profit from our expertise on a fee-for-service contract.
SATT Conectus Alsace Strasbourg, France - www.conectus.fr
The Société d’Accélération du Transfert de Technologies (SATT) Conectus Alsace is one-stop shop for all operators of research and development on its territory of intervention. The SATT Conectus Alsace is based on a proven track record of economic value creation (12 enterprises created, 3 in creation and 3 licenses on 23 projects funded). It exploits the results of an internationally competitive research in the fields of biology, chemistry, engineering and physics. It is organized according to the strategic sectors of the territory based on clusters and devices recognized (Alsace Biovalley, Véhicule du Futur, Alsace EnergieVie, RTRA Chimie). Conectus Alsace offers solutions tailored to meet your needs: - advice, expertise - analyses, studies - R&D programs - Transfer of technologies, skills and know-how.
TECHNOLOGY OFFER The researchers represented by Conectus Alsace® develop technologies in a wide range of domains: drug discovery, drug delivery, bio and chemo informatics, medical imaging, diagnostics… and a variety of therapeutic domains: cancer, neurology, cardiovascular, inflammation, pain… In oncology we have a range of technology offers between the diagnostic to the cancer treatment. A panel of these technologies is visible on our website: http://www.conectus.fr/medias/oncology- event/ot-cancero.pdf
INTEREST IN THE ONCOLOGY VIRTUAL MATCHMAKING For us it is a great opportunity to present the technologies developed in our laboratories.
SOM Biotech Barcelona, Spain - www.sombiotech.com
SOM Biotech, a drug reprofiling company using ligand based in silico technology.
SOM Biotech is a small biopharmaceutical company focused in drug reprofiling, a strategy that bypasses the delays, risks and costs of drug discovery and early stage development. We rely on a proprietary computational platform for ligand based in silico screening that allows us to identify potential new therapeutic uses for known compounds. Once SOM Biotech has validated the new therapeutic activity with appropriate in vitro and in vivo models of disease; the company obtains strong patent protection, and pursues licensing and joint-venture agreements for the further development of the reprofiled drugs. Founded in December 2009, SOM Biotech is located at the Barcelona Science Park and is part of the Bioincubator PCB-Santander. We have a multidisciplinary team with experience in drug development in the pharmaceutical and biotech industry. Through the vision that drug repositioning has made invaluable contributions to quality of life and healthcare improvement, SOM Biotech is using its best technology and team based efforts to maximize the value of drugs in the market.
TECHNOLOGY OFFER In the context of a project aimed at finding new treatments for Glioblastoma Multiforme (an aggressive brain tumour with orphan drug status), SOM Biotech has identified a new small molecule integrin inhibitor with a new chemical scaffold and potential use as anticancer agent. The hit compound has activity as alphaVbeta3 and alphaVbeta5 integrin inhibitor and also inhibits cell growth to several cancer cell lines. It is a good candidate for a lead optimization program aimed at designing new anticancer agents with a high therapeutic index and potential for development on different forms of solid tumours, including cancers with orphan disease status. Moreover, SOM Biotech has identified 4 approved drugs with anti-cancer activity in vitro. These drugs are marketed for indications other than cancer, and could be reprofiled as new treatment options for oncology indications, such as T-cell lymphoma.
INTEREST IN THE ONCOLOGY VIRTUAL MATCHMAKING SOM business model is based in licensing and joint-venture agreements for the development of reprofiled drugs. It is our expertise to identify the new use, validate it in non-clinical models and getting a strong intellectual protection. We are looking for a partner for the development of candidate drugs for oncology indications. One of them is a NCE in the lead optimization phase, and 4 others are reprofiled drugs already used in clinics for indications other than cancer. We are open to any type of agreement, from a full-sell of the project to a joint-venture for development.
Theradex (Europe) Ltd Crawley, UK - www.theradex.com Other locations: London and USA
Theradex is a full service niche clinical research organisation specialising in oncology research. The company has been in business for almost 30 years Theradex® is an international contract research organization providing complete professional services for the clinical research and development of pharmaceutical compounds, medical devices and diagnostic tests in the areas of oncology and life-threatening diseases. Theradex® conducts studies which lead to marketing approval of significant medical advances; and has built a reputation on assuring the scientific objectivity and meticulous quality control that fulfils all regulatory requirements. Our expertise is also available to assist client personnel in expedited development planning and execution. For twenty-five years, Theradex® has held the Clinical Trials Monitoring Service Contract for the National Cancer Institute in the United States. In that time, we have not only gained a wealth of experience in the treatment of cancer and allied diseases, but have also formed long-standing relationships with oncology thought-leaders, academic and non-academic institutions, regulatory personnel and, most importantly, our clients. We demonstrate time and time again our flexibility and commitment to quality, which larger CROs are often unable to attain. On behalf of our clients and through our global development capability, Theradex® provides a comprehensive array of services.
TECHNOLOGY OFFER Full clinical development services in oncology Phases I-IV.
INTEREST IN THE ONCOLOGY VIRTUAL MATCHMAKING Theradex wishes to engage with any companies wishing to discuss their oncology clinical development requirement with a good reliable and experienced oncology CRO with international experience in all phases of oncology clinical trials.
TRANSGENE SA Strasbourg, France - www.transgene.fr
Transgene is a fully integrated biopharmaceutical company that designs and develops cutting- edge immunotherapeutic products to treat cancers and chronic infectious diseases. Transgene is a fully integrated biopharmaceutical company that designs and develops cutting-edge immunotherapeutic products to treat cancers and chronic infectious diseases. Our expertise covers all stages of product development, from research to the manufacture of clinical batches, and the conducting of clinical trials. Five products are currently in clinical development: TG4010, JX594/TG6006, TG4001, and TG4040 in phase II trials and TG4023 in phase I trial. Transgene has concluded strategic agreements with Novartis for the development of TG4010 to treat various cancers and with US-based Jennerex Biotherapeutics, Inc. (www.jennerex.com), to develop and market JX594/TG6006, an oncolytic product. Transgene is also a partner in a major, externally funded, research project (ADNA program) that aims to achieve individualized medicine for cancers, infectious diseases and genetic diseases. The program focuses on the identification and development of biological markers, and its findings are already making a substantial contribution to the future development of our products. The company has a number of exclusive and innovative technologies using viral vectors. Its proprietary gene transfer technology is protected by an extensive portfolio of intellectual property rights. Transgene is committed to scientific excellence and medical innovation, with the company’s top level scientists focusing on applying their research findings to developing new therapies in order to treat unmet medical needs. A strong pre-clinical pipeline bears witness to this commitment. For over 25 years Transgene has built on its recognized scientific expertise. Today, we are a major player in the field of immunotherapy.
TECHNOLOGY OFFER Tumour progression is controlled by tumour-associated macrophages and metastasis-induced bone destruction by osteoclasts, both cell types depending on the CD115-CSF-1 pathway for their differentiation and function. Progression of many epithelial cancers (breast, ovary, cervix, endometrium) is associated with increased expression of CD115 and CSF-1 by tumour cells. We show here in a mouse tumour model that treatment with a monoclonal antibody (mAb) blocking host CD115 decreases tumour growth and expression of the F4/80 macrophage marker in tumours. In another mouse model of breast cancer metastasis-induced osteolysis, the anti-mouse CD115 mAb inhibits bone destruction and the serum osteoclast marker TRAP5b. We have generated a monoclonal antibody to human CD115, TG3003, which inhibits the receptor function through a non- ligand competitive mode of action. This mAb down-regulates CSF-1-dependent osteoclast differentiation and osteoclastic bone resorption in vitro. TG3003 is a humanized IgG1 with antibody- dependent cell cytotoxicity (ADCC) towards a CD115-positive recombinant tumour cell line. It does not exert significant cytotoxic activity towards normal human primary CD115-positive monocytes and does not kill CD115-high dendritic cells by ADCC in vitro, which should minimize toxicity in vivo. Through its multiple intervention points on cancer targets, TG3003 represents a promising candidate for the treatment of solid tumours associated with bone metastases.
INTEREST IN THE ONCOLOGY VIRTUAL MATCHMAKING Looking for licensing-out, co-development or external funding for start-up creation around TG3003.
UROLEAD SAS Strasbourg, France -www.urolead.com
Urolead offers the best predictive way to test a drug candidate against cancer in the area of Prostate/Bladder or Kidney, by providing human tumour grafted on mice that can mimic human response TECHNOLOGY OFFER We provide the pharmaceutical and biopharmaceutical industries with a unique experimental research platform combining both in vivo pharmacological models and in vitro assays, using human urologic tumours xenografted in nude mice.
INTEREST IN THE ONCOLOGY VIRTUAL MATCHMAKING Our intent is to find business opportunities considering mainly: - Finding companies interested by our unique services - Partnering with CROs in countries where Urolead is not developed nor has no agreement